Obesity – Page 22 – Talk Bio

Actionable Insights Powered by AI

AstraZeneca Acquires Option for SixPeaks: A Potential Breakthrough in Obesity Biotechnology

2 years ago talkbio0Tagged Acquisition (action), AstraZeneca, Biotechnology, Obesity, SixPeaks, Ventures, Versant

AstraZeneca, SixPeaks, Versant Ventures, obesity, biotechnology, acquisition, option, breakthrough.

Hims & Hers Expands Weight-Loss Solutions with GLP-1 Injections

2 years ago talkbio0Tagged Glucagon-Like Peptide 1, Hims & Hers, Injection of therapeutic agent, metabolic health, Obesity, Prescription procedure, Telemedicine, Weight-Loss

Hims & Hers, GLP-1 injections, weight-loss, telehealth, prescription medication, obesity treatment, metabolic health

Beyond Weight Loss: Wegovy’s Cardiovascular Benefits Uncovered in New Study

2 years ago talkbio0Tagged Administration occupational activities, Benefit, Cardiovascular system, Clinical Research, Diabetes, Glucagon-Like Peptide-1 Receptor, heart health, Obesity, Wegovy

Wegovy, cardiovascular benefits, weight loss, GLP-1 receptor agonist, heart health, obesity treatment, diabetes management, clinical study.

Novo Nordisk’s Wegovy Shines as a Promising Obesity Treatment: A 4-Year Analysis

2 years ago talkbio0Tagged 4-year, Approved, blockbuster drug, Clinical Trials, Glucagon-Like Peptide-1 Receptor, Nordisk, Obesity, semaglutide, United States Food and Drug Administration, Wegovy

Novo Nordisk, Wegovy, obesity treatment, weight loss, 4-year data, clinical trials, blockbuster drug, GLP-1 receptor agonist, FDA approval, semaglutide.

Novo Nordisk’s Wegovy Demonstrates Long-Term Weight Loss Success in New Analysis

2 years ago talkbio0Tagged Analysis of substances, Cardiovascular Diseases, Diabetes, Long-term, Nordisk, Obesity, semaglutide, Wegovy, Weight Loss

Novo Nordisk, Wegovy, weight loss, long-term, four years, analysis, obesity treatment, semaglutide, sustained weight loss, diabetes, cardiovascular disease.

Novo Nordisk and Metaphore Pharmaceuticals Join Forces in a $600 Million Partnership to Pioneer Innovative Obesity Treatments

2 years ago talkbio0Tagged Metabolic Diseases, next-generation, Nordisk, Obesity, Partnership, pharmaceutical collaboration, weight loss medications

Novo Nordisk, Metaphore Pharmaceuticals, obesity drugs, next-generation treatments, $600 million deal, partnership, pharmaceutical collaboration, weight loss medications, metabolic disorders.

Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management

2 years ago talkbio0Tagged Administration occupational activities, Biological Factors, Collaboration, Diabetes, Eli, Eli Lilly, GLUCOSE CONTROL, Innovent, Metabolic Diseases, next-generation therapy, Obesity, Phase 3 trials

Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.

Amgen Discontinues Obesity Program, Shifts Focus to MariTide after Phase 1 Results

2 years ago talkbio0Tagged amgen, asset, Biotechnology, Clinical Trials, Drug Development, MariTide, Obesity, Phase 1 (qualifier value)

Amgen, obesity asset, phase 1 results, MariTide, drug development, biotechnology, clinical trials

Novo Nordisk Faces Scrutiny Over High Prices of Ozempic and Wegovy

2 years ago talkbio0Tagged Diabetes, Nordisk, Obesity, Prices, Sanders, Senator Bernie, Wegovy

Novo Nordisk, Ozempic, Wegovy, drug prices, Senator Bernie Sanders, diabetes, obesity

Metsera Emerges with $290M to Rival Obesity Pharmaceutical Giants Lilly and Novo

2 years ago talkbio0Tagged Eli Lilly, Metsera, Novo, Obesity, Phase I injectable, Product containing glucagon-like peptide 1 receptor agonist (product)

Metsera, $290M funding, Obesity treatment, Challenge Lilly and Novo, GLP-1 receptor agonist (Phase I injectable)